0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
From the Centers for Disease Control and Prevention |

Malaria in Multiple Family Members—Chicago, Illinois, 2006 FREE

JAMA. 2007;297(20):2191-2193. doi:10.1001/jama.297.20.2191.
Text Size: A A A
Published online

MMWR. 2006;55:645-648

1 table omitted

Human malaria is a parasitic disease transmitted through the bite of an infected female Anopheles mosquito. Most malaria cases in the United States occur in travelers who recently visited areas where malaria is endemic without taking adequate chemoprophylaxis.1 This report describes five cases of Plasmodium falciparum malaria that occurred in a family residing near Chicago, Illinois, during 2006. These cases underscore the importance of malaria-prevention measures (e.g., avoidance of mosquito bites and appropriate chemoprophylaxis) for travelers to malaria-endemic areas.

In February 2006, three boys aged 10, 6, and 4 years (patients 1, 2, and 3, respectively) were hospitalized for complicated P. falciparum malaria (i.e., malaria with potentially life-threatening manifestations). They were members of a family of seven, including the two parents, the three male patients, and two girls aged 11 and 2 years (patients 4 and 5, respectively), all of whom had traveled in 2005 and early 2006 to Nigeria, the native country of the parents and their oldest daughter. The four youngest children, including the three boys and the girl aged 2 years, were born in the United States, where the family had lived for 10 years.

Before the trip to Nigeria, the parents had asked their local health department about malaria medications. They were told that antimalarial drugs were available. However, they assumed incorrectly that the drugs were to be taken for treatment only and did not realize that the drugs could also be used for chemoprophylaxis; therefore, they did not request a prescription. The mother and the three youngest children spent 3 months in Nigeria; the father and the two oldest children stayed 5 weeks. The family visited friends and relatives in various locations of Nigeria (e.g., Abuja, Ilorin, Kano, and Lagos) without taking malaria chemoprophylaxis. During their travel, three of the children (patients 2, 3, and 5) had onset of separate febrile episodes that were treated uneventfully with antibiotics, ibuprofen, and sulfadoxine-pyrimethamine (Fansidar®), all recommended by a local physician. All family members returned to the United States in January 2006.

Two weeks after their return, the four oldest children (the three boys and the girl aged 11 years) had onset of influenza-like symptoms, including fever and headaches, and were treated at a local clinic with antipyretics and amoxicillin. Three days later, the parents noticed that the eyes of the three boys (patients 1, 2, and 3) had yellow scleras and took them to the hospital. On examination, all three were febrile and jaundiced, and the boy aged 10 years (patient 1) appeared ill and had pallor and severe back pain. Blood smears confirmed the diagnosis of P. falciparum malaria in all three patients; the boy aged 4 years (patient 3) had a high parasitemia at 4.8%. Other abnormal laboratory findings for all three patients included anemia, thrombocytopenia, hyperbilirubinemia, and elevated aminotransferase levels. The boy aged 10 years (patient 1) had severe metabolic acidosis and hypoglycemia (glucose: 25 mg/dL; blood pH: 7.1; base excess: -15 mEq/L).

Because patients 1, 2, and 3 each had at least one manifestation of complicated malaria (e.g., acidosis, hypoglycemia, severe anemia, or jaundice),2 all three were admitted to the pediatric intensive care unit and treated with intravenous quinidine combined with doxycycline (patient 1) or clindamycin (patients 2 and 3, in whom doxycycline was contraindicated because they were aged <8 years).3 The boy aged 10 years (patient 1) had a hyperhemolytic syndrome with markedly decreased hemoglobin concentration, severe metabolic acidosis, and hypoglycemia and therefore required intubation, dextrose infusion, transfusions of red blood cells and fresh frozen plasma, erythrophoresis (exchange transfusion), and plasmapheresis. The boy aged 4 years (patient 3) required packed red blood cell transfusions for anemia. The boys aged 6 and 4 years (patients 2 and 3, respectively) had prolonged QT intervals on electrocardiogram, which resolved after discontinuation of the intravenous quinidine. Parasitemia in all three patients had resolved by the third day of hospitalization, and all three children were discharged in good condition after 1 week.

The day after hospitalization of the three boys, their two sisters also were tested by blood smear and determined to be infected with P. falciparum, albeit at lower parasite densities. The girl aged 11 years (patient 4) had fever and headache; her sister aged 2 years (patient 5) was asymptomatic. Both were hospitalized in a general pediatric unit and treated successfully with oral quinine combined with either doxycycline or clindamycin; parasitemia resolved by the third day of hospitalization.

The parents reported that patients 1 and 5 had sickle cell disease. Subsequent hemoglobin electrophoresis indicated that all five children had either sickle cell disease (SS) or sickle cell trait (SA).

Infection with P. falciparum was confirmed by polymerase chain reaction (PCR) performed at CDC on the pretreatment blood specimens of patients 1, 2, 3, and 4.4 No pretreatment blood sample was available for patient 5; PCR results for a posttreatment specimen (obtained 1 day after completion of quinine therapy) were negative.

Both parents were asymptomatic. They consulted their primary physician, who treated them presumptively with mefloquine, without taking a blood smear.

Reported by:

D Glikman, MD, JF Marcinak, MD, RS Daum, MD, Section of Infectious Diseases, CP Montgomery, MD, KS Hoehn, MD, Section of Critical Care Medicine, Dept of Pediatrics, J Anastasi, MD, Dept of Pathology, Univ of Chicago, Chicago, Illinois. HS Bishop, P Nguyen-Dinh, MD, Div of Parasitic Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (proposed), CDC.

CDC Editorial Note:

The high attack rate reported in the family described in this report illustrates the elevated risk for malaria in travelers to sub-Saharan Africa. Among 1,190 imported cases of malaria reported in the United States during 2004 for which the region of acquisition was known, 68% were acquired in Africa, with the majority of cases attributed to P. falciparum,1 the species that most typically causes severe malaria in humans. Three of the five infected children described in this report had complicated malaria and required treatment in the intensive care unit.

All five children had the sickle cell gene; two were SS homozygotes, and three were heterozygotes. The sickle cell gene is found more commonly in persons of African descent because the sickle cell trait confers a selective advantage, resistance to severe malaria.5 In a recent large cohort study of Kenyan children, the sickle cell trait was found to be approximately 50% protective against mild clinical malaria, 75% protective against admission to the hospital for malaria, and 90% protective against severe or complicated malaria.6 However, two of the three patients with sickle cell trait described in this report (patients 2 and 3) still had complicated malaria. Patient 1 had a low parasitemia but was severely ill, probably because of hyperhemolysis related to sickle cell disease. In a study from Nigeria, malaria was found to be an important risk factor for hyperhemolytic crisis in children with sickle cell disease.7

These five cases underscore the importance of preventive measures, including avoidance of mosquito bites and appropriate chemoprophylaxis, for travelers to malaria-endemic areas.8 The majority of cases of imported malaria occur in travelers who have not taken appropriate prophylaxis. Among U.S. civilians with imported malaria reported in 2004, approximately 76% had not taken any prophylaxis or had taken prophylaxis that did not conform to CDC recommendations.1 Failure to take prophylaxis is a major contributing factor to malaria cases and deaths in U.S. travelers.9 Especially low compliance rates are reported among U.S. residents born in malaria-endemic areas who return to their country of origin to visit friends and relatives, a situation derived from various cultural and economic factors, such as misperception that malaria is not a serious illness or lack of adequate insurance coverage.10 Acquired immunity to malaria is never complete and persists only through continual reexposure to malaria. Persons born in a malaria-endemic country who move to a nonendemic area are at risk for symptomatic and severe malaria upon return to their native country, unless they take preventive measures. Travelers who have onset of malaria while visiting a malaria-endemic country might receive a treatment that does not adhere to CDC guidelines; for example, the drug used to treat presumed malaria in three of the children during their travel (sulfadoxine-pyrimethamine) is no longer recommended by CDC because of drug resistance and adverse drug effects.3

Prophylaxis recommendations should be based on risk for malaria acquisition, occurrence of drug resistance in the areas to be visited, and traveler characteristics (e.g., age, reproductive status, and medical history). For example, chloroquine-resistant malaria is widespread in sub-Saharan Africa, including Nigeria, and resistance to sulfadoxine-pyrimethamine also occurs in this region. Malaria can affect both adults and children. Among 732 cases of malaria in U.S. civilians of known age reported in the United States during 2004, approximately 11% were in children aged <15 years. Detailed recommendations for preventing malaria in traveling infants and children are available from CDC.* In addition, recommendations for prevention of malaria in travelers of all ages are available.† Finally, CDC biannually publishes recommendations in Health Information for International Travel (i.e., “The Yellow Book”),8 which is available for purchase (telephone, 800-545-2522) and available and updated more frequently on the CDC website.‡

‡Available at http://www.cdc.gov/travel.

REFERENCES
CDC.  Malaria surveillance—United States, 2004.  MMWR Surveill Summ. 2006;55:(No. SS-04)  23-37
PubMed
World Health Organization. Management of severe malaria—a practical handbook. 2nd ed. Geneva, Switzerland: World Health Organization; 2000. Available at http://www.who.int/malaria/docs/hbsm_toc.htm
CDC. Treatment of malaria (guidelines for clinicians). Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm
Johnston SP, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, da Silva AJ. PCR as a confirmatory technique for laboratory diagnosis of malaria.  J Clin Microbiol. 2006;44:1087-1089
PubMed   |  Link to Article
Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection.  Br Med J. 1954;1:290-294
PubMed   |  Link to Article
Williams TN, Mwangi TW, Wambua S.  et al.  Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases.  J Infect Dis. 2005;192:178-186
PubMed   |  Link to Article
Juwah AI, Nlemadim EU, Kaine W. Types of anaemic crises in paediatric patients with sickle cell anaemia seen in Enugu, Nigeria.  Arch Dis Child. 2004;89:572-576
PubMed   |  Link to Article
CDC. Health information for international travel, 2005-2006. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC; 2005. Available at http://www.cdc.gov/travel
Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001.  Ann Intern Med. 2004;141:547-555
PubMed   |  Link to Article
Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad.  Ann Intern Med. 2005;142:67-72
PubMed   |  Link to Article

Figures

Tables

References

CDC.  Malaria surveillance—United States, 2004.  MMWR Surveill Summ. 2006;55:(No. SS-04)  23-37
PubMed
World Health Organization. Management of severe malaria—a practical handbook. 2nd ed. Geneva, Switzerland: World Health Organization; 2000. Available at http://www.who.int/malaria/docs/hbsm_toc.htm
CDC. Treatment of malaria (guidelines for clinicians). Atlanta, GA: US Department of Health and Human Services, CDC; 2006. Available at http://www.cdc.gov/malaria/diagnosis_treatment/tx_clinicians.htm
Johnston SP, Pieniazek NJ, Xayavong MV, Slemenda SB, Wilkins PP, da Silva AJ. PCR as a confirmatory technique for laboratory diagnosis of malaria.  J Clin Microbiol. 2006;44:1087-1089
PubMed   |  Link to Article
Allison AC. Protection afforded by sickle-cell trait against subtertian malarial infection.  Br Med J. 1954;1:290-294
PubMed   |  Link to Article
Williams TN, Mwangi TW, Wambua S.  et al.  Sickle cell trait and the risk of Plasmodium falciparum malaria and other childhood diseases.  J Infect Dis. 2005;192:178-186
PubMed   |  Link to Article
Juwah AI, Nlemadim EU, Kaine W. Types of anaemic crises in paediatric patients with sickle cell anaemia seen in Enugu, Nigeria.  Arch Dis Child. 2004;89:572-576
PubMed   |  Link to Article
CDC. Health information for international travel, 2005-2006. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC; 2005. Available at http://www.cdc.gov/travel
Newman RD, Parise ME, Barber AM, Steketee RW. Malaria-related deaths among U.S. travelers, 1963-2001.  Ann Intern Med. 2004;141:547-555
PubMed   |  Link to Article
Angell SY, Cetron MS. Health disparities among travelers visiting friends and relatives abroad.  Ann Intern Med. 2005;142:67-72
PubMed   |  Link to Article
CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles
JAMAevidence.com

The Rational Clinical Examination
Make the Diagnosis: Malaria

The Rational Clinical Examination
Original Article: Does This Patient Have Malaria?